Oncolytic virotherapy is an emerging treatment modality that uses replication-competent
viruses to destroy cancers. Recent advances include preclinical proof of feasibility for a …

New vessel formation (angiogenesis) is an essential physiological process for embryologic
development, normal growth, and tissue repair. Angiogenesis is tightly regulated at the …

Here, we report the results of a phase I/II, single-arm study (UMIN-CTR Clinical Trial Registry
UMIN000002661) assessing the safety (primary endpoint) of G47∆, a triple-mutated …

Oncolytic viruses (OVs) are tumor-selective, multi-mechanistic antitumor agents. They kill
infected cancer and associated endothelial cells via direct oncolysis, and uninfected cells …

Pathological angiogenesis—driven by an imbalance of pro-and antiangiogenic signaling—
is a hallmark of many diseases, both malignant and benign. Unlike in the healthy adult in …

In this review we will describe eight commonly used rat brain tumor models and their
application for the development of novel therapeutic and diagnostic modalities. The C6, 9L …

Despite recent advances in both surgery and chemoradiotherapy, mortality rates for
advanced cancer remain high. There is a pressing need for novel therapeutic strategies; one …

Glioblastoma (GBM) is an immunosuppressive, lethal brain tumor. Despite advances in
molecular understanding and therapies, the clinical benefits have remained limited, and the …

Immune checkpoint inhibitors and adoptive transfer of gene-engineered T cells have
emerged as novel therapeutic modalities for hard-to-treat solid tumors; however, many …

Oncolytic viruses (OVs) are an emerging class of targeted anticancer therapies designed to
selectively infect, replicate in, and lyse malignant cells without causing harm to normal …